Tigecycline and bacteremia-the dangers of post hoc analysis of pooled data

Clinical Infectious Diseases

Volumn 51, Issue 7, 2010, Pages 867-868

  Tarchini, Giorgio ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; LEVOFLOXACIN; NAFCILLIN; OXACILLIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIOSTASIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DATA INTERPRETATION, STATISTICAL; HUMANS; MINOCYCLINE; TREATMENT OUTCOME;

EID: 77957840634     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656289     Document Type: Letter

References (15)

1. Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010;50(2):229-238.
2. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9:251-261.
3. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658-4666.
4. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41:S341-S353.
5. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [study ID numbers: 3074A1-301-WW; ClinicalTrials.gov identifier: NCT00081744]. BMC Infect Dis 2005; 5:88.
6. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3:35-47.
7. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41(suppl 5):S354-S367.
8. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63(1):52-61.
9. Tanaseanu C, Bergallo C, Teglia O, et al; 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61:329-338.
10. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, doubleblind, randomized study. J Antimicrob Chemother 2008; 62(suppl 1):i17-28.
11. Vasilev K, Reshedko G, Orasan R, et al. A phase 3, open-label, noncomparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62(suppl 1):i29-40.
12. Rodvold K, Gotfried M, Cwik M, Korth-Bradley J, Dukart G, Ellis-Grosse E. Serum, tissue and body fluid concentrations of tigecycline after a single 100-mg dose. J Antimicrob Chemother 2006; 58:1221-1229.
13. MacGowan AP. Tigecycline pharmacokinetic/ pharmacodynamic update. J Antimicrob Chemother 2008; 62(suppl 1):i11-16.
14. Chang F-Y, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003; 82(5):333-339.
15. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27-S72.